
## **Listing of Claims**:



- 2. (Previously Presented) The method of claim 11 wherein the newborn subject is a mammal in the first four weeks after birth.
- 3. (Cancelled)
- 4. (Cancelled)
- 5. (Previously Presented) The method of claim 11 wherein the xenon is administered in combination with a sedative, an anaesthetic agent or a further analgesic agent.
- 6. (Previously Presented) The method of claim 11 wherein the medicament is in gaseous form.
- 7. (Cancelled)
- 8. (Previously Presented) The method of claim 11 wherein the medicament is in liquid form.
- 9. (Cancelled)
- 10. (Cancelled)
- 11. (Currently Amended) A method of providing analgesia in a <u>human</u> newborn subject, the method comprising administering <u>a therapeutically effective amount of an analgesic</u> to a <u>human</u> newborn subject <u>experiencing pain or stress sufficient to necessitate administration of the analgesic</u>, wherein the <u>analgesic is xenon</u>. in need of analgesia a therapeutically effective amount of xenon.

12. (Currently Amended) A method of providing analgesia in a <u>human</u> fetal subject, the method comprising administering <u>a therapeutically effective amount of an analgesic</u> to <u>a the mother of a the human</u> fetal subject, the fetal subject <u>experiencing pain or stress sufficient to necessitate administration of the analgesic</u>, wherein the analgesic is xenon in need of analgesia, a therapeutically effective amount of xenon the fetal subject.

- 13. (Previously Presented) A method accordingly to claim 11 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.
- 14. (Previously Presented) A method according to claim 11 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.
- 15. (Previously Presented) A method according to claim 11 wherein the xenon is administered in the form of a lipid emulsion.
- 16. (Previously Presented) A method according to claim 11 wherein the xenon is administered intraveneously, neuraxially or transdermally.
- 17. (Previously Presented) A method accordingly to claim 12 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.
- 18. (Previously Presented) A method according to claim 12 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.
- 19. (Previously Presented) A method according to claim 12 wherein the xenon is administered in the form of a lipid emulsion.
- 20. (Previously Presented) A method according to claim 12 wherein the xenon is administered intraveneously, neuraxially or transdermally.

Docket No.: 2839/46401

21. (Previously Presented) The method according to claim 12, wherein the xenon is

administered to the mother prior to labor.

22. (Previously Presented) The method according to claim 12, wherein the xenon is

administered to the mother during labor.

23. (Previously Presented) The method of claim 5, wherein the further analgesic agent is an

alpha-2-adrenergic agonist, an opiate, or a non-steroidal anti-inflammatory drug.

24. (Previously Presented) The method of claim 5, wherein the sedative or anaesthetic agent

promotes GABAergic activity.